Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Millipore Is Exploring Its Strategic Options
by Ann M. Thayer
March 1, 2010
| A version of this story appeared in
Volume 88, Issue 9
Millipore has confirmed that it has hired financial adviser Goldman Sachs and is evaluating strategic alternatives, including a possible merger or sale of the company. On Feb. 22, the Billerica, Mass.-based life sciences products company saw its stock price spike about 40% and then settle down about 25% above its price the day before, to $87.35 per share, on rumors that it was to be acquired. In particular, lab equipment maker Thermo Fisher Scientific was reported to have made a $6 billion takeover bid. Millipore had sales of $1.65 billion and net income of $177 million in 2009.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter